Inogen Inc (NASDAQ:INGN) – Equities research analysts at KeyCorp reduced their Q4 2018 earnings per share estimates for shares of Inogen in a report issued on Wednesday, November 7th. KeyCorp analyst M. Mishan now expects that the medical technology company will earn $0.22 per share for the quarter, down from their previous estimate of $0.46.
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.21. The firm had revenue of $95.29 million for the quarter, compared to analyst estimates of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The business’s revenue for the quarter was up 38.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS.
Several other equities research analysts have also issued reports on INGN. ValuEngine lowered shares of Inogen from a “buy” rating to a “hold” rating in a report on Wednesday. Piper Jaffray Companies boosted their price target on shares of Inogen to $245.00 and gave the company an “overweight” rating in a report on Tuesday, August 7th. BidaskClub lowered shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $276.00 price target on the stock in a report on Tuesday, August 28th. Finally, Needham & Company LLC boosted their price target on shares of Inogen from $215.00 to $254.00 and gave the company a “strong-buy” rating in a report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $244.67.
Shares of Inogen stock opened at $148.51 on Friday. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of 113.37, a price-to-earnings-growth ratio of 3.06 and a beta of 1.56. Inogen has a 52-week low of $111.49 and a 52-week high of $287.79.
In other news, Director Heath Lukatch sold 500 shares of the company’s stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $193.97, for a total value of $96,985.00. Following the sale, the director now owns 1,489 shares of the company’s stock, valued at approximately $288,821.33. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ray Benjamin M. Anderson sold 1,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $246.22, for a total transaction of $246,220.00. Following the completion of the sale, the director now directly owns 1,989 shares in the company, valued at approximately $489,731.58. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,000 shares of company stock worth $11,098,610. 5.29% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. OppenheimerFunds Inc. grew its holdings in shares of Inogen by 40.3% in the 2nd quarter. OppenheimerFunds Inc. now owns 286,147 shares of the medical technology company’s stock worth $53,318,000 after purchasing an additional 82,164 shares during the last quarter. WINTON GROUP Ltd grew its holdings in shares of Inogen by 382.8% in the 2nd quarter. WINTON GROUP Ltd now owns 67,012 shares of the medical technology company’s stock worth $12,486,000 after purchasing an additional 53,133 shares during the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in shares of Inogen in the 2nd quarter worth about $186,000. BlackRock Inc. grew its holdings in shares of Inogen by 7.2% in the 2nd quarter. BlackRock Inc. now owns 2,591,083 shares of the medical technology company’s stock worth $482,796,000 after purchasing an additional 173,035 shares during the last quarter. Finally, California Public Employees Retirement System grew its holdings in Inogen by 4.6% during the 2nd quarter. California Public Employees Retirement System now owns 31,149 shares of the medical technology company’s stock worth $5,804,000 after acquiring an additional 1,376 shares during the last quarter. 96.67% of the stock is currently owned by institutional investors and hedge funds.
Inogen Company Profile
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
See Also: Google Finance Portfolio Workaround
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.